Furthermore, sWGS analysis revealed gain of the region containing ERBB2 in cfDNA and CTCs, indicating either a switch from HER2-negative metastatic disease or the expansion of a pre-existing subclonal HER2-amplified population, potentially responsible for lack of response to lines of treatment. Here, ERBB2 is linked to metastatic neoplasm.